Healthy Extracts Reports Q2 2024 Net Revenue Up 54 percent to Record High, Driving Positive EPS - StockTitan
| HYEX Stock | USD 2.37 0.07 3.04% |
Slightly above 55% of Grey Cloak's investors are presently thinking to get in. The analysis of current outlook of investing in Grey Cloak Tech suggests that some traders are interested regarding Grey Cloak's prospects. Grey Cloak's investing sentiment can be driven by a variety of factors including economic data, Grey Cloak's earnings reports, geopolitical events, and overall market trends.
Grey |
Healthy Extracts Reports Q2 2024 Net Revenue Up 54 percent to Record High, Driving Positive EPS StockTitan
Read at news.google.com
 |
Grey Cloak Fundamental Analysis
We analyze Grey Cloak's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Grey Cloak using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Grey Cloak based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
Grey Cloak is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Grey Cloak Tech Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Grey Cloak otc stock to make a market-neutral strategy. Peer analysis of Grey Cloak could also be used in its relative valuation, which is a method of valuing Grey Cloak by comparing valuation metrics with similar companies.
Peers
Grey Cloak Related Equities
| AKAN | Akanda Corp | 2.94 | ||||
| COLL | Collegium Pharmaceutical | 0.68 | ||||
| EOLS | Evolus | 0.80 | ||||
| INCR | INC Research | 1.48 | ||||
| ANIP | ANI Pharmaceuticals | 3.64 | ||||
| YCBD | CbdMD | 3.92 | ||||
| BFRI | Biofrontera | 9.09 |
Additional Tools for Grey OTC Stock Analysis
When running Grey Cloak's price analysis, check to measure Grey Cloak's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Grey Cloak is operating at the current time. Most of Grey Cloak's value examination focuses on studying past and present price action to predict the probability of Grey Cloak's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Grey Cloak's price. Additionally, you may evaluate how the addition of Grey Cloak to your portfolios can decrease your overall portfolio volatility.